Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The immune system, in the context of desensitization to *Phleum pratense* (timothy grass) allergens, is the biological target for allergen immunotherapy. The goal is to modulate immune responses—specifically those that cause allergic reactions—to reduce or eliminate clinical symptoms upon exposure to grass pollen. Allergen immunotherapy introduces small, controlled doses of these allergens over time to induce immunologic tolerance by shifting the immune response away from a pathogenic Th2/IgE-dominated profile toward regulatory T cell activity and increased production of blocking antibodies such as IgG4. Key molecular players include allergen-specific IgE and IgG4, regulatory T cells, and major allergens like Phl p 1 & Phl p 5. Therapeutic approaches involve subcutaneous or sublingual administration of standardized *Phleum pratense* extracts.
Modulation of humoral and cellular immunity to induce tolerance to Phleum pratense allergens. Shift from Th2/IgE-mediated response to regulatory T cell activity and increased IgG4 production.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune System (Desensitization to Phleum pratense Allergens) (N/A).